Amphotericin B and its new formulations: Pharmacologic characteristics, clinical efficacy, and tolerability

Transplant Infectious Disease

Volumn 1, Issue 4, 1999, Pages 273-283

  Tiphine, M ^a   Letscher Bru, V ^b   Herbrecht, R ^c  

^a Pharmacie   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Amphotericin B colloidal dispersion; Amphotericin B lipid complex; Aspergillosis; Candidiasis; Febrile neutropenia; Fusariosis; Liposomal amphotericin B; Mucormycosis; Nephrotoxicity

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT;

BONE MARROW TRANSPLANTATION; CHEMISTRY; COMPARATIVE STUDY; DRUG ADMINISTRATION; HUMAN; MYCOSIS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MYCOSES; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 0033301541     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.1999.010406.x     Document Type: Article

References (107)

1. BOLARD J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta 1986: 864: 257-304.
2. BRAJTBURG J, BOLARD J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996: 9: 512-531.
3. VERTUT-CROQUIN A, BOLARD J, GARY-BOBO CM. Transfer of amphotericin B from gel state vesicles to mycoplasma cells: biphasic action on potassium transport and permeability. Antimicrob Agents Chemother 1985: 28: 167-171.
4. BRAJTBURG J, ELBERG S, SCHWARTZ DR, et al. Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob Agents Chemother 1985: 27: 172-176.
5. SURARIT R, SHEPHERD MG. The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans. J Med Vet Mycol 1987: 25: 403-413.
6. BARCHIESI F, COLOMBO AL, MCGOUGH DA, RINALDI MG. Comparative study of both macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol 1994: 32: 2494-2500.
7. FRANZOT SP, HAMDAN JS. In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob Agents Chemother 1996: 40: 822-824.
8. HANSON LH, STEVENS DA. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother 1992: 36: 486-488.
9. PFALLER MA, MESSER S, JONES RN. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997: 41: 233-235.
10. ROTOWA NA, SHADOMY HJ, SHADOMY S. In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses 1990: 33: 203-211.
11. ABI-SAID D, ANASSIE EJ. New emerging fungal pathogens. Baillieres Clin Infect Dis 1995: 2: 71-87.
12. WALSH TJ, MELCHER GP, RINALDI MG, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990: 28: 1616-1622.
13. BOSWELL GW, BUELL D, BEKERSKY I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 1998: 38: 583-592.
14. HEINEMANN V, BOSSE D, JEHN U, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother 1997: 41: 1275-1280.
15. KAN VL, BENNETT JE, AMANTEA MA, et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis 1991: 164: 418-421.
16. SANDERS SW, BUCHI KN, GODDARD MS, LANG JK, TOLMAN KG. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 1991: 35: 1029-1034.
17. HELNEMANN V, KAHNY B, JEHN U, et al. Serum pharmacology of amphotericin B applied in lipid emulsions. Antimicrob Agents Chemother 1997: 41: 728-732.
18. ATKINSON AJ, JR, BENNETT JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978: 13: 271-276.
19. DANESHMEND TK, WARNOCK DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983: 8: 17-42.
20. CHRISTIANSEN KJ, BERNARD EM, GOLD JW, ARMSTRONG D. Distribution and activity of amphotericin B in humans. J Infect Dis 1985: 152: 1037-1043.
21. WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998: 27: 603-618.
22. KHOO SH, BOND J, DENNING DW. Administering amphotericin B - a practical approach. J Antimicrob Chemother 1994: 33: 203-213.
23. DENNING DW. Treatment of invasive aspergillosis. J Infect 1994: 28 (Suppl 1): 25-33.
24. REX JH, BENNETT JE, SUGAR AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994: 331: 1325-1330.
25. EDWARDS JE, BODEY GP, BOWDEN RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997: 25: 43-59.
26. ANAISSIE E, BODEY GP, KANTARJIAN H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991: 91: 142-150.
27. JOLY V, AUBRY P, NDAYIRAGIDE A, et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996: 23: 556-562.
28. VAN DER HORST CM, SAAG MS, CLOUD GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997: 337: 15-21.
29. MORRISON VA, MCGLAVE PB. Mucormycosis in the BMT population. Bone Marrow Transplant 1993: 11: 383-388.
30. YOHAI RA, BULLOCK JD, AZIZ AA, MARKERT RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994: 39: 3-22.
31. HERBRECHT R, KOENIG H, WALLER J, LIU KL, GUEHO E. Trichosporon infections: clinical manifestations and treatment. J Mycol Med 1993: 3: 129-136.
32. GALLIS HA, DREW RH, PICKARD W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990: 12: 308-329.
33. GOODWIN SD, CLEARY JD, WALAWANDER CA, TAYLOR JW, GRASELA TH, JR. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995: 20: 755-761.
34. LEVY M, DOMARATZKI J, KOREN G. Amphotericin-induced heart-rate decrease in children. Clin Pediatr 1995: 34: 358-364.
35. ROSA G, DELL'UTRI D, CONTI G, et al. Efficacy of nefopam for the prevention and treatment of amphotericin B-induced shivering. Arch Intern Med 1997: 157: 1589-1592.
36. GALES MA, GALES BJ. Rapid infusion of amphotericin B in dextrose. Ann Pharmacother 1995: 29: 523-529.
37. ELLIS ME, AL HOKAIL AA, CLINK HM, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992: 36: 172-179.
38. ARNING M, AUL C, DRESEN B, SCHNEIDER W. The influence of the duration of infusion on the acute toxicity of amphotericin B. Comparison of two hour versus four hour infusions. Immun Infekt 1991: 19: 80-83.
39. CLEARY JD, WEISDORF D, FLETCHER CV. Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intell Clin Pharm 1988: 22: 769-772.
40. CRUZ JM, PEACOCK JE, JR, LOOMER L, et al. Rapid intravenous infusion of amphotericin B: a pilot study. Am J Med 1992: 93: 123-130.
41. ANAISSIE EJ, WHITE M, UZUN O, et al. Amphotericin B lipid complex versus amphotericin B for the treatment of hematogenous and invasive candidiasis: a prospective randomized multicenter trial. Proceeding of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 17-20 1995, 330.
42. CLEMENTS JS, JR, PEACOCK JE, JR. Amphotericin B revisited: reassessment of toxicity. Am J Med 1990: 88: 22N-27N.
43. PRENTICE HG, HANN IM, HERBRECHT R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997: 98: 711-718.
44. GERKENS JF, BRANCH RA. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther 1980: 214: 306-311.
45. OHNISHI A, OHNISHI T, STEVENHEAD W, et al. Sodium status influences chronic amphotericin B nephrotoxicity in rats. Antimicrob Agents Chemother 1989: 33: 1222-1227.
46. SABRA R, BRANCH RA. Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimicrob Agents Chemother 1991: 35: 2509-2514.
47. TOLINS JP, RAIJ L. Chronic amphotericin B nephrotoxicity in the rat, protective effect of prophylactic salt loading. Am J Kidney Dis 1988: 11: 313-317.
48. SAWAYA BP, WEIHPRECHT H, CAMPBELL WR, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991: 87: 2097-2107.
49. HEIDEMANN HT, GERKENS JF, SPICKARD WA, JACKSON EK, BRANCH RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983: 75: 476-481.
50. BRANCH RA, JACKSON ER, JACQZ E, et al. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr 1987: 65: 500-506.
51. LLANOS A, CIEZA J, BERNARDO J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991: 40: 302-308.
52. SAWAYA BP, BRIGGS JP, SCHNERMANN J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995: 6: 154-164.
53. ANDERSON CM. Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care? West J Med 1995: 162: 313-317.
54. KINTZEL PE, SMITH GH. Practical guidelines for preparing and administering amphotericin B. Am J Hosp Pharm 1992: 49: 1156-1164.
55. BERNARDO JF, MURAKAMI S, BRANCH RA, SABRA R. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. Nephron 1995: 70: 235-241.
56. MAYER J, DOUBEK M, VORLICEK J. Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 1999: 7: 51-55.
57. SAID R, MARIN P, ANICAMA H, QUINTANILLA A, LEVIN ML. Effect of mannitol on acute amphotericin B nephrotoxicity. Res Exp Med 1980: 177: 85-69.
58. CAMP MJ, WINGARD JR, GILMORE CE, et al. Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients. Antimicrob Agents Chemother 1998: 42: 3103-3106.
59. KIRSH R, GOLDSTEIN R, TARLOFF J, et al. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 1988: 158: 1065-1070.
60. JOLY V, FARINOTTI R, SAINT-JULIEN L, CHERON M, CARBON C, YENI P. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob Agents Chemother 1994: 38: 177-183.
61. TRISSEL LA. Amphotericin B does not mix with fat emulsion. Am J Health Syst Pharm 1995: 52: 1463-1464.
62. RANCHERE JY, LATOUR JF, FUHRMANN C, LAGALLARDE C, LOREUIL F. Amphotericin B intralipid formulation: stability and particle size. J Antimicrob Chemother 1996: 37: 1165-1169.
63. CAILLOT D, CHAVANET P, CASASNOVAS O, et al. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis 1992: 11: 722-725.
64. CHAVANET P, GARRY I, CHARLIER N, CAILLOT D, KISTERMAN JP, D'ATHIS M. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 1992: 305: 921-925.
65. JOLY V, GEOFFRAY C, REYNES J, et al. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. J Antimicrob Chemother 1996: 38: 117-126.
66. HERBRECHT R, SOSA C, HIMY R, VILLARD O. Successful treatment of visceral leishmaniasis with high-dose amphotericin B diluted in fat emulsion: a case report. Trans R Soc Trop Med Hyg 1996: 90: 322-323.
67. THAKUR CP. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Trans R Soc Trop Med Hyg 1994: 88: 698-699.
68. SORKINE P, NAGAR H, WEINBROUM A, et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med 1996: 24: 1311-1315.
69. SCHÖFFSKI P, FREUND M, WUNDER R, et al. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Br Med J 1998: 317: 379-384.
70. FIELDING RM, SINGER AW, WANG LH, BABBAR S, GUO LS. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1992: 36: 299-307.
71. JANKNEGT R, DE MARIE S, BAKKER-WOUDENBERG IA, CROMMELIN DJ. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 1992: 23: 279-291.
72. STEVENS DA. Overview of amphotericin B colloidal dispersion (Amphocil). J Infect 1994: 28 (Suppl 1): 45-49.
73. HERBRECHT R, LETSCHER V, ANDRES E, CAVALIER A. Safety and efficacy of amphotericin B colloidal dispersion. An overview. Chemotherapy 1999: 45: 67-76.
74. HERBRECHT R, LETSCHER V, ANDRES E, KUSNE S, GURWITH M, OBERLING F. Zygomycosis treated with amphotericin B colloidal dispersion. A review of 22 cases. Blood 1996: 88: 502a.
75. WHITE MH, ANAISSIE EJ, KUSNE S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997:24:635-642.
76. BOWDEN R, CHANDRASEKAR P, WHITE M, VAN BURIK JA, WINGARD J, AND THE MULTICENTER ASPERGILLUS STUDY GROUP. A double-blind randomized controlled trial of Amphocil versus amphotericin B in invasive aspergillosis in immunocompromised patients. Proceeding of the 10th International Conference on Infections in the Immunocompromised Host, 1998.
77. WHITE MH, BOWDEN RA, SANDLER ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998: 27: 296-302.
78. HERBRECHT R. Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 1997: 16: 74-80.
79. BOWDEN RA, CAYS M, GOOLEY T, MAMELOK RD, VAN BURIK JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996: 173: 1208-1215.
80. GURWITH M, MAMELOK R, PIETRELLI L, DU MC. Renal sparing by amphotericin B colloidal dispersion: clinical experience in 572 patients. Chemotherapy 1999: 45: 39-47.
81. HERBRECHT R, ANDRES E, LETSCHER V, et al. Treatment with high cumulative doses of Amphotericin B colloidal dispersion. Efficacy and tolerance in 96 patients. Blood 1996: 88: 502a.
82. BROGDEN RN, GOA KL, COUKELL AJ. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis. Drugs 1998: 56: 365-383.
83. JANOFF AS, BONI LT, POPESCU MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988: 85: 6122-6126.
84. OLSEN SJ, SWERDEL MR, BLUE B, CLARK JM, BONNER DP. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991: 43: 831-835.
85. CLARK JM, WHITNEY RR, OLSEN SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991: 35: 615-621.
86. DIX SP, WINGARD JR. Amphotericin B Lipid Complex: review of safety, pharmacokinetics and efficacity. Drugs Today 1996: 32 (Suppl. G): 19-25.
87. SWENSON CE, PERKINS WR, ROBERTS P, et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother 1998: 42: 767-771.
88. WALSH TJ, HIEMENZ JW, SEIBEL NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998: 26: 1383-1396.
89. WINGARD JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997: 19: 343-347.
90. SHARKEY PK, GRAYBILL JR, JOHNSON ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996: 22: 315-321.
91. LISTER J. Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996: 57 (Suppl.): 18-23.
92. HERBRECHT R, TIMMEL MC, TABONE MD, et al. Amphotericin B lipid complex (ABLC) treatment in children with invasive fungal infections. Proceeding of the Second Meeting of the European Haematology Association, Paris, 29 May-1st June 1996.
93. HAY RJ. Liposomal amphotericin B, AmBisome. J Infect 1994: 28 (Suppl 1): 35-43.
94. DE MARIE S, JANKNEGT R, BAKKER-WOUDENBERG IA. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994: 33: 907-916.
95. ADLER-MOORE J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994: 14 (Suppl 5): S3-S7.
96. PROFFITT RT, SATORIUS A, CHIANG SM, SULLIVAN L, ADLER-MOORE JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991: 28 (Suppl B): 49-61.
97. TOLLEMAR J, RINGDEN O, TYDEN G. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients: efficacy and safety evaluation. Clin Transplant 1990: 4: 167-175.
98. RINGDEN O, MEUNIER F, TOLLEMAR J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991: 28 (Suppl B): 73-82.
99. ELLIS M, SPENCE D, DE PAUW B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998: 27: 1406-1412.
100. LEENDERS AC, DAENEN S, JANSEN RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998: 103: 205-212.
101. LEENDERS AC, REISS P, PORTEGIES P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997: 11: 1463-1471.
102. WALSH TJ, FINBERG RW, ARNDT C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999: 340: 764-771.
103. TOLLEMAR J, HOCKERSTEDT K, ERICZON BG, JALANKO H, RINGDEN O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 1995: 59: 45-50.
104. TOLLEMAR J, RINGDEN O, ANDERSSON S, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993: 25: 1495-149.
105. DAVIDSON RN, DI MARTINO L, GRADONI L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996: 22: 938-943.
106. MEYERHOFF A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999: 28: 42-48.
107. WINGARD JR, WHITE MH, ANAISSE EJ, et al. A randomized double-blind safety study of Ambisome and Abelcet in febrile neutropenic patients. Proceeding of the Focus on Fungal Infections 9, San Diego, 17-19 March 1999, O15.